Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer

Frank A Sinicrope, Koichi Okamoto, Pashtoon M. Kasi, Hisato Kawakami

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and epigenetic events that occur with tumor initiation and progression. Large variation exists in individual patient prognosis and response to chemotherapy, caused by molecular heterogeneity. Certain biomarkers have been identified that can predict clinical outcome beyond tumor staging, and inform treatment selection. Molecular testing is routinely performed in clinical practice for the selection of patients for targeted biological agents or immunotherapy, and is advocated for prognostic stratification. Estimating prognosis can avoid undertreatment or overtreatment and also guide the intensity of patient follow-up. Classifiers of CRC have been developed that integrate genetic and/or epigenetic features. The mutational status of KRAS and BRAF V600E oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. Gene expression profiling has also been used to subtype CRCs and can overcome the limitations of single/limited gene testing. A recent effort identified 4 consensus molecular subtypes of biological relevance that were associated with different patient outcomes. Efforts to validate and refine these subtypes to include additional genomic features are ongoing. The focus of this article is to highlight molecular markers that can inform clinical decision-making in patients with CRC.

Original languageEnglish (US)
JournalClinical Gastroenterology and Hepatology
DOIs
StateAccepted/In press - 2016

Fingerprint

Colorectal Neoplasms
Biomarkers
Epigenomics
CpG Islands
DNA Mismatch Repair
Neoplasm Staging
Biological Factors
Gene Expression Profiling
Therapeutics
Oncogenes
Immunotherapy
Colonic Neoplasms
Patient Selection
Phenotype
Drug Therapy
Genes
Neoplasms

Keywords

  • Anti-EGFR
  • Anti-VEGF
  • Biologics
  • BRAF
  • Colorectal Cancer
  • DNA Mismatch Repair
  • Immunotherapy
  • Molecular Subtypes
  • MSI
  • Predictive Markers
  • Prognostic Markers
  • RAS
  • Targeted Therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. / Sinicrope, Frank A; Okamoto, Koichi; Kasi, Pashtoon M.; Kawakami, Hisato.

In: Clinical Gastroenterology and Hepatology, 2016.

Research output: Contribution to journalArticle

@article{ef524830a0d4494bad1fdea1e6b628d8,
title = "Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer",
abstract = "Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and epigenetic events that occur with tumor initiation and progression. Large variation exists in individual patient prognosis and response to chemotherapy, caused by molecular heterogeneity. Certain biomarkers have been identified that can predict clinical outcome beyond tumor staging, and inform treatment selection. Molecular testing is routinely performed in clinical practice for the selection of patients for targeted biological agents or immunotherapy, and is advocated for prognostic stratification. Estimating prognosis can avoid undertreatment or overtreatment and also guide the intensity of patient follow-up. Classifiers of CRC have been developed that integrate genetic and/or epigenetic features. The mutational status of KRAS and BRAF V600E oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. Gene expression profiling has also been used to subtype CRCs and can overcome the limitations of single/limited gene testing. A recent effort identified 4 consensus molecular subtypes of biological relevance that were associated with different patient outcomes. Efforts to validate and refine these subtypes to include additional genomic features are ongoing. The focus of this article is to highlight molecular markers that can inform clinical decision-making in patients with CRC.",
keywords = "Anti-EGFR, Anti-VEGF, Biologics, BRAF, Colorectal Cancer, DNA Mismatch Repair, Immunotherapy, Molecular Subtypes, MSI, Predictive Markers, Prognostic Markers, RAS, Targeted Therapy",
author = "Sinicrope, {Frank A} and Koichi Okamoto and Kasi, {Pashtoon M.} and Hisato Kawakami",
year = "2016",
doi = "10.1016/j.cgh.2016.02.008",
language = "English (US)",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer

AU - Sinicrope, Frank A

AU - Okamoto, Koichi

AU - Kasi, Pashtoon M.

AU - Kawakami, Hisato

PY - 2016

Y1 - 2016

N2 - Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and epigenetic events that occur with tumor initiation and progression. Large variation exists in individual patient prognosis and response to chemotherapy, caused by molecular heterogeneity. Certain biomarkers have been identified that can predict clinical outcome beyond tumor staging, and inform treatment selection. Molecular testing is routinely performed in clinical practice for the selection of patients for targeted biological agents or immunotherapy, and is advocated for prognostic stratification. Estimating prognosis can avoid undertreatment or overtreatment and also guide the intensity of patient follow-up. Classifiers of CRC have been developed that integrate genetic and/or epigenetic features. The mutational status of KRAS and BRAF V600E oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. Gene expression profiling has also been used to subtype CRCs and can overcome the limitations of single/limited gene testing. A recent effort identified 4 consensus molecular subtypes of biological relevance that were associated with different patient outcomes. Efforts to validate and refine these subtypes to include additional genomic features are ongoing. The focus of this article is to highlight molecular markers that can inform clinical decision-making in patients with CRC.

AB - Colorectal cancer (CRC) is a disease in which pathogenesis is influenced by genetic and epigenetic events that occur with tumor initiation and progression. Large variation exists in individual patient prognosis and response to chemotherapy, caused by molecular heterogeneity. Certain biomarkers have been identified that can predict clinical outcome beyond tumor staging, and inform treatment selection. Molecular testing is routinely performed in clinical practice for the selection of patients for targeted biological agents or immunotherapy, and is advocated for prognostic stratification. Estimating prognosis can avoid undertreatment or overtreatment and also guide the intensity of patient follow-up. Classifiers of CRC have been developed that integrate genetic and/or epigenetic features. The mutational status of KRAS and BRAF V600E oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. Gene expression profiling has also been used to subtype CRCs and can overcome the limitations of single/limited gene testing. A recent effort identified 4 consensus molecular subtypes of biological relevance that were associated with different patient outcomes. Efforts to validate and refine these subtypes to include additional genomic features are ongoing. The focus of this article is to highlight molecular markers that can inform clinical decision-making in patients with CRC.

KW - Anti-EGFR

KW - Anti-VEGF

KW - Biologics

KW - BRAF

KW - Colorectal Cancer

KW - DNA Mismatch Repair

KW - Immunotherapy

KW - Molecular Subtypes

KW - MSI

KW - Predictive Markers

KW - Prognostic Markers

KW - RAS

KW - Targeted Therapy

UR - http://www.scopus.com/inward/record.url?scp=84961231260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961231260&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2016.02.008

DO - 10.1016/j.cgh.2016.02.008

M3 - Article

C2 - 26872400

AN - SCOPUS:84961231260

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

ER -